Atypical situations in treatment of chronic hepatitis C patients
Abstract
The aim. To share experience of patient management with persistent hepatitis C virus infection at different stages of liver damage.
Clinical cases data. 3 clinical cases of antiviral therapy at «difficult-to-treat» patients with various forms of HCV-infection are presented. Presented cases include: 1-st genotype HCV, two previous ineffective attempts of antiviral therapy and successful prolonged course; with decompensated liver cirrhosis; 1-st virus genotype and metabolic syndrome. Features of such patient management are demonstrated.
Conclusion. The choice of optimal medical tactics should base on virologic characteristic, stage of hepatitis, presence of concomitant diseases, efficacy of previous courses of antiviral therapy and on specific personal features of patient and his/her tuning on coping with disease. There is no doubt, that individual approach will allow to improve essentially treatment results in many cases.
About the Authors
A. V. LapshinRussian Federation
A. O. Buyeverov
Russian Federation
М. V. Mayevskaya
Russian Federation
V. Т. Ivashkin
Russian Federation
References
1. Богомолов П.О., Буеверов А.О. Эффективность и безопасность комбинированной терапии отечественными противовирусными препаратами хронического гепатита С // Фарматека. – 2006. – № 5. – С. 28–32.
2. Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В.Т. Ивашкина. – 2-е изд., испр. и доп. – М.: Изд. дом «М-Вести», 2005. – С. 115–151.
3. Afdhal N.H., Dieterich D.T., Pockros P.J. et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study // Gastroenterology. – 2004. – Vol. 126. – P. 1302–1311.
4. Belfort R., Harrison S.A., Brown K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis // N. Engl. J. Med. – 2006. – Vol. 355. – P. 2297–2307.
5. Jensen D.M., Morgan T.R., Marcellin P. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy // Hepatology. – 2006. – Vol. 43. – P. 954–960.
6. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection // World J. Gastroenterol. – 2006. – Vol. 12. – P. 6756–6765.
7. NIH Consensus Statement on Management of Hepatitis C: 2002 // NIH Consens. State Sci. Statements. – 2002. – Vol. 19. – P. 1–46.
8. Pazienza V., Clement S., Pugnale P. et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms // Hepatology. – 2007. – Vol. 45. – P. 1164–1171.
9. Pearlman B., Ehleben C., Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2b plus weight-based ribavirin in a difficult-to-treat population of genotype 1-infected slow responders // Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27–31, 2006. – Boston, Massachusetts [Abstract 343].
10. Zeuzem S., Buti M., Ferenci P. et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia // J. Hepatol. – 2006. – Vol. 44. – P. 97–103.
Review
For citations:
Lapshin A.V., Buyeverov A.O., Mayevskaya М.V., Ivashkin V.Т. Atypical situations in treatment of chronic hepatitis C patients. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2008;18(2):72-78. (In Russ.)
Views:
3
Email this article 
